{"id":208,"date":"2013-11-26T20:21:13","date_gmt":"2013-11-26T20:21:13","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/?p=208"},"modified":"2017-08-21T13:03:25","modified_gmt":"2017-08-21T13:03:25","slug":"primary-care-corner-with-dr-geoffrey-modest-and-more-on-pharma-shenanigans","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2013\/11\/26\/primary-care-corner-with-dr-geoffrey-modest-and-more-on-pharma-shenanigans\/","title":{"rendered":"Primary Care Corner with Dr. Geoffrey Modest: And more on pharma shenanigans"},"content":{"rendered":"<p>so, just after i posted the blog yesterday, this came through:\u00a0 \u201cFDA Opens Door to Wider Avandia Prescribing\u201d \u2013 see <a href=\"http:\/\/www.medpagetoday.com\/Endocrinology\/Diabetes\/43110?xid=nl_mpt_DHE_2013-11-26&amp;utm_content=&amp;utm_medium=email&amp;utm_campaign=DailyHeadlines&amp;utm_source=WC&amp;eun=g748274d0r&amp;userid=748274&amp;email=gmodest@uphams.org&amp;mu_id=5928254\">http:\/\/www.medpagetoday.com\/Endocrinology\/Diabetes\/43110?xid=nl_mpt_DHE_2013-11-26&amp;utm_content=&amp;utm_medium=email&amp;utm_campaign=DailyHeadlines&amp;utm_source=WC&amp;eun=g748274d0r&amp;userid=748274&amp;email=gmodest@uphams.org&amp;mu_id=5928254<\/a>, or your local newspaper. has the slight whiff of the hand of big pharma&#8230;..<\/p>\n<p>i can\u2019t figure out why this is an issue (expect from drug company pressure). the data are pretty clear that rosiglitazone (avandia) in several studies is associated with more clinical heart disease.\u00a0 it has adverse lipid effects. and, if one were to choose a glitazone, there are data that pioglitazone is beneficial to lipids and leads to favorable cardiac outcomes\u00a0 (see dm pioglit PROACTIVE study. lancet 2005, or <i>Lancet <\/i>2005; 366: 1279\u201389).<\/p>\n<p>and the beat goes on.<\/p>\n<p>&nbsp;<\/p>\n<p>geoff<\/p>\n","protected":false},"excerpt":{"rendered":"<p>more on pharma shenanigans [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2013\/11\/26\/primary-care-corner-with-dr-geoffrey-modest-and-more-on-pharma-shenanigans\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":148,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14283],"tags":[],"class_list":["post-208","post","type-post","status-publish","format-standard","hentry","category-archive"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/users\/148"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/comments?post=208"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/208\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/media?parent=208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/categories?post=208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/tags?post=208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}